Overcoming drug resistance in HIV-1 chemotherapy: The binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease

Protein Science

Volumn 11, Issue 8, 2002, Pages 1908-1916

  Ohtaka, Hiroyasu ^a   Velázquez Campoy, Adrian ^a   Xie, Dong ^a   Freire, Ernesto ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Amprenavir; Drug resistance; HIV 1 protease; HIV 1 protease inhibitors; Isothermal titration calorimetry; TMC 126

Indexed keywords

AMPRENAVIR; INDINAVIR; KNI 764; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TMC 126; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CALORIMETRY; DRUG BINDING; DRUG STRUCTURE; ENTHALPY; ENTROPY; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; THERMODYNAMICS; TITRIMETRY; VIRUS MUTANT; VIRUS STRAIN;

BINDING SITES; CALORIMETRY; CARBAMATES; DRUG DESIGN; DRUG RESISTANCE, VIRAL; ESCHERICHIA COLI; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; KINETICS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; PROTEIN BINDING; SULFONAMIDES; THERMODYNAMICS; URETHANE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0036078615     PISSN: 09618368     EISSN: None     Source Type: Journal    
DOI: 10.1110/ps.0206402     Document Type: Article

References (28)

1. Molecular basis of HIV-1 protease drug resistance: Structural analysis of mutant proteases complexed with cyclic urea inhibitors
2. Counteracting HIV-1 protease drug resistance: Structural analysis of mutant proteases complexed with XV638 and SD146, cyclic urea amides with broad specificities
3. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
4. Designing drugs against heterogeneous targets
5. Enthalpy and heat capacity changes for the proton dissociation of various buffer components in 0.1M potassium chloride
6. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor
7. Crystal structures of complexes of a peptidic inhibitor with wild-type and two mutant HIV-1 proteases
8. VMD - Visual molecular dynamics
9. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV
10. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease
11. Crystal structure of HIV-1 protease in complex with VX_478, a potent and orally bioavailable inhibitor of the enzyme
12. Resistance to HIV protease inhibitors: A comparison of enzyme inhibition and antiviral potency
13. Direct measurement of protein binding energetics by isothermal titration calorimetry
14. Structural and kinetic analyses of the protease from an Amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to Saquinavir and resensitized to Amprenavir
15. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor
16. Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants
17. Drug-resistance patterns of Saquinavir and other HIV proteinase inhibitors
18. Exact analysis of competition ligand binding by displacement isothermal titration calorimetry
19. HIV protease inhibitors - Resistance issues
20. The effect of inhibitor binding on the structural stability and cooperativity of the HIV-1 protease
21. The structural stability of the HIV-1 protease
22. The thermodynamic basis of resistance to HIV-1 protease inhibition. Calorimetric analysis of the V82/I84V active site resistant mutant
23. Incorporating target heterogeneity in drug design
24. Thermodynamic dissection of the binding energetics of KNI-272, a powerful HIV-1 protease inhibitor
25. The binding energetics of first and second generation HIV-1 protease inhibitors: Implications for drug design
26. The application of thermodynamic methods in drug design
27. Dissection of binding energy with native and ligand-bound protein stabilities: Determining the affinity of ultratight-binding inhibitors of HIV-1 protease and its drug resistance mutants
28. A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC- 126), and the selection of a novel (A28S) mutation in the protease active site